Realizing synergies and maximizing value through post-merger integration.
Another wave of consolidation is hitting the life sciences industry. In 2009, a combination of mega-mergers, diversification plays and tuck-in acquisitions have characterized the merger and acquisition (M&A) landscape in the pharmaceutical sector. The trend is expected to continue as CEOs respond to industry pressures and opportunities to create value through M&A and divestitures. However, it is still unclear whether these transactions ever fulfill the value they promise.